[Ranitidine protects the human stomach and duodenal mucosa against low-dose acetylsalicylic acid].
In a randomized double-blind study the gastroduodenal tolerability of 300 mg ASS daily has been evaluated in the presence of 150 mg ranitidine bid or placebo in 20 healthy volunteers using upper GI-endoscopy. The treatment period lasted 14 days. Endoscopic controls were performed at entry, and repeated at day 7 and day 14. At entry, the mean endoscopic score averaged 0.8 +/- 0.1 in the ASS/placebo-group and 1.0 +/- 0.0 in the ASS/ranitidine group. 300 mg ASS daily induced in the placebo experiments marked gastroduodenal alterations both at day 7 and day 14 (4.7 +/- 1.2 and 6.5 +/- 2.1, respectively). Concomitant administration of 150 mg ranitidine bid afforded almost full protection against 300 mg ASS daily both on day 7 and day 14 (1.9 +/- 0.6 and 2.1 +/- 0.8, respectively) (p less than 0.05). Our data suggest that coadministration of ranitidine 150 mg bid reduces almost completely gastroduodenal lesions evoked by acetylsalicylic acid 300 mg daily.
Müller
P
P
Medizinische Universitätsklinik, Gastroenterologische Abteilung, Heidelberg.
Damman
H G
HG
Marinis
E
E
Simon
B
B
D000328:Adult; D001241:Aspirin / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005753:Gastric Mucosa / Q000187:drug effects*; D005756:Gastritis / Q000139:chemically induced / Q000517:prevention & control*; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced / Q000517:prevention & control*; D005773:Gastroscopy; D006801:Humans; D008297:Male; D016032:Randomized Controlled Trials as Topic; D011899:Ranitidine / Q000008:administration & dosage*
D011899:Ranitidine; D001241:Aspirin
Ranitidin schützt die menschliche Magen- und Duodenalschleimhaut gegenüber niedrig dosierter Acetylsalicylsäure.